Diagnostic Testing of STDs Market Size, Share, Growth, and Industry Analysis, By Type (Chlamydia, Gonorrhea, Syphilis, HIV, HPV+pap smear, HSV, Chancroid), By Application (Hospitals, Clinics), Regional Insights and Forecast to 2035

Unique Information about the Diagnostic Testing of STDs Market

Diagnostic Testing of STDs Market size is estimated at USD 129830.2 million in 2026 and expected to rise to USD 278896.12 million by 2035, experiencing a CAGR of 8.87%.

The Diagnostic Testing of STDs Market is experiencing significant expansion due to rising screening volumes, increased awareness programs, and broader access to laboratory diagnostics. More than 1 million sexually transmitted infections are acquired globally every day, while over 374 million new cases of chlamydia, gonorrhea, syphilis, and trichomoniasis are reported annually. Molecular diagnostic platforms account for approximately 58% of advanced STD testing procedures because of their sensitivity levels exceeding 95% in many clinical settings. Point-of-care testing contributes nearly 27% of testing volumes, reducing turnaround times from 72 hours to less than 30 minutes. More than 65% of healthcare providers now utilize multiplex testing systems capable of detecting multiple infections from a single sample. The Diagnostic Testing of STDs Market Report indicates increasing demand for automated analyzers, digital reporting systems, and self-collection diagnostic kits across healthcare networks.

The United States represents one of the largest contributors to the Diagnostic Testing of STDs Market Size, supported by high screening rates and advanced laboratory infrastructure. More than 2.5 million reported cases of chlamydia, gonorrhea, and syphilis are recorded annually across the country. Chlamydia accounts for approximately 52% of reported bacterial STD cases, while gonorrhea contributes nearly 27%. Around 80% of public health laboratories in the United States utilize nucleic acid amplification tests (NAATs) for STD diagnosis. Over 65 million STD screening procedures are performed annually across hospitals, clinics, and diagnostic laboratories. More than 70% of sexually active individuals aged 18–35 undergo at least one screening test during healthcare visits. The Diagnostic Testing of STDs Industry Analysis highlights increasing adoption of rapid tests, with turnaround times reduced by nearly 60% compared to conventional laboratory methods.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: Approximately 78% of healthcare facilities prioritize routine screening programs, 72% of laboratories utilize molecular diagnostics, 69% of testing centers report increasing patient volumes, and 64% of public health agencies support expanded screening initiatives, accelerating Diagnostic Testing of STDs Market Growth.
• Major Market Restraint: Around 41% of patients delay testing because of social stigma, 37% avoid screening due to privacy concerns, 33% experience limited access to healthcare facilities, and 29% face diagnostic affordability barriers, restricting broader market penetration.
• Emerging Trends: Nearly 61% of new testing platforms incorporate rapid diagnostics, 56% support self-collection procedures, 49% utilize digital reporting systems, and 44% integrate multiplex testing capabilities, strengthening Diagnostic Testing of STDs Market Trends across healthcare settings.
• Regional Leadership: North America accounts for approximately 38% of global testing activity, Europe contributes 27%, Asia-Pacific represents 24%, and Middle East & Africa holds nearly 11%, reflecting strong regional concentration within the Diagnostic Testing of STDs Market Share.
• Competitive Landscape: Approximately 48% of industry participation is controlled by major multinational diagnostic companies, 26% by specialized molecular testing providers, 16% by point-of-care manufacturers, and 10% by emerging innovators introducing advanced screening technologies.
• Market Segmentation: Molecular diagnostics represent approximately 58% of testing procedures, rapid diagnostic tests contribute 24%, immunoassays account for 12%, and conventional laboratory methods represent 6%, highlighting technology preferences throughout the Diagnostic Testing of STDs Market.
• Recent Development: Nearly 63% of recently introduced diagnostic products support multiplex detection, 54% feature automated workflows, 46% reduce turnaround times below 30 minutes, and 38% incorporate digital connectivity for enhanced patient management and reporting.

Diagnostic Testing of STDs Market Latest Trends

The Diagnostic Testing of STDs Market Trends are increasingly influenced by rapid technological advancements and rising screening awareness. More than 58% of newly installed diagnostic systems utilize molecular testing platforms capable of identifying multiple infections simultaneously. Multiplex assays have demonstrated detection accuracy levels exceeding 95% for common sexually transmitted infections, leading to broader adoption among hospitals and clinics. Self-testing and self-collection kits have emerged as a major trend, accounting for approximately 22% of newly introduced STD testing solutions. Studies indicate that self-collection methods increase participation rates by nearly 35% among populations previously reluctant to undergo testing. Digital health integration is also transforming the market, with approximately 47% of laboratories implementing electronic reporting and cloud-based result management systems.

Rapid diagnostic tests continue to gain traction, representing nearly 24% of testing volumes globally. Many modern rapid tests provide results within 15 to 30 minutes, compared with traditional laboratory methods requiring 24 to 72 hours. Healthcare providers report that faster diagnosis improves treatment initiation rates by approximately 40%. Artificial intelligence-assisted diagnostic interpretation is being introduced in nearly 18% of advanced laboratory environments. Automated analyzers now process more than 1,000 samples per day in large healthcare facilities, improving workflow efficiency by approximately 50%. These developments continue to strengthen Diagnostic Testing of STDs Market Outlook, supporting increased accessibility, operational efficiency, and diagnostic accuracy across healthcare systems.

Diagnostic Testing of STDs Market Dynamics

DRIVER

"Rising demand for routine STD screening programs"

The primary growth driver within the Diagnostic Testing of STDs Market is the increasing implementation of routine screening initiatives. More than 374 million new cases of curable sexually transmitted infections are reported globally every year, creating substantial demand for diagnostic services. Approximately 72% of healthcare providers now recommend periodic screening for sexually active populations. Screening participation among individuals aged 18 to 34 has increased by nearly 31% over the past decade. Public health agencies in more than 80 countries have expanded testing accessibility through community clinics and outreach programs. Molecular diagnostic utilization exceeds 58% of total testing procedures due to accuracy rates above 95%. Hospitals report that early detection programs reduce transmission risks by approximately 45%, reinforcing demand throughout the Diagnostic Testing of STDs Market Analysis.

RESTRAINT

"Social stigma and limited testing participation"

Despite increasing awareness, social stigma remains a significant challenge affecting Diagnostic Testing of STDs Market Growth. Approximately 41% of individuals report discomfort discussing sexually transmitted infections with healthcare professionals. Nearly 37% avoid screening because of privacy concerns, while 29% delay testing until symptoms become severe. Rural regions experience testing rates approximately 24% lower than urban areas due to healthcare accessibility limitations. Surveys indicate that around 33% of high-risk individuals remain unscreened annually. In some developing regions, diagnostic infrastructure reaches less than 50% of the population, limiting access to laboratory services. These barriers reduce testing frequency and slow adoption of advanced diagnostic technologies despite growing disease prevalence.

OPPORTUNITY

"Expansion of point-of-care and home-based testing"

Significant opportunities exist through expansion of point-of-care diagnostics and home testing solutions. Point-of-care testing currently accounts for approximately 27% of total STD screening procedures and continues to expand. Modern rapid tests deliver results within 30 minutes while maintaining accuracy rates above 90%. Self-testing kits have demonstrated participation increases of nearly 35% among underserved populations. Approximately 56% of newly developed diagnostic platforms now support decentralized testing models. Digital health integration enables secure result transmission and consultation services for more than 40% of users. Healthcare organizations increasingly invest in remote diagnostics to improve accessibility and reduce healthcare facility burdens. These trends create substantial Diagnostic Testing of STDs Market Opportunities across developed and emerging economies.

CHALLENGE

"Diagnostic accuracy and regulatory compliance requirements"

Maintaining diagnostic accuracy while complying with regulatory standards remains a critical challenge. More than 65% of healthcare providers require sensitivity rates above 95% before adopting new testing platforms. Regulatory approval processes can extend beyond 12 months for advanced diagnostic products. Laboratories conduct quality control procedures on nearly 100% of diagnostic batches to maintain compliance standards. False-positive rates above 3% and false-negative rates above 5% can significantly impact clinical outcomes and patient confidence. Approximately 46% of manufacturers identify regulatory documentation requirements as a major operational challenge. Additionally, integration of advanced molecular diagnostics requires specialized training for nearly 40% of laboratory personnel, increasing implementation complexity throughout the Diagnostic Testing of STDs Industry Report.

Segmentation Analysis

The Diagnostic Testing of STDs Market is strongly driven by infection-specific testing demand and healthcare service distribution. Chlamydia testing leads with 29% of total testing volume, followed by HIV at 24% and gonorrhea at 16%. HPV and Pap smear testing account for 14%, while syphilis, HSV, and chancroid represent 9%, 6%, and 2%, respectively. Hospitals perform 57% of tests, while clinics contribute 43% through screening and outpatient diagnostic programs.

Download FREE Sample to learn more about this report.

By Type

Chlamydia: Chlamydia testing represents approximately 29% of the Diagnostic Testing of STDs Market Share, making it the largest testing category worldwide. More than 129 million new chlamydia infections are estimated globally each year, creating substantial demand for diagnostic screening. Approximately 68% of screening procedures utilize nucleic acid amplification tests (NAATs) because sensitivity levels frequently exceed 95%. Females account for nearly 58% of testing volumes, primarily due to reproductive health screening programs. Individuals aged 15–24 years represent approximately 43% of diagnosed cases. More than 70% of public health screening initiatives include chlamydia testing as a primary diagnostic component.

Gonorrhea: Gonorrhea testing contributes approximately 16% of the Diagnostic Testing of STDs Market Size. More than 82 million new gonorrhea infections occur annually worldwide. Around 74% of gonorrhea diagnostic procedures are conducted using molecular testing platforms due to high detection accuracy. Antimicrobial-resistant gonorrhea strains account for nearly 32% of monitored cases in several surveillance programs, increasing testing requirements. Approximately 61% of screening activities occur within hospitals and specialized sexual health clinics. Dual testing for chlamydia and gonorrhea is performed in nearly 67% of screening encounters.

Syphilis: Syphilis testing represents approximately 9% of the Diagnostic Testing of STDs Market Share. More than 8 million new syphilis infections are recorded globally each year. Screening demand has increased because congenital syphilis cases have risen by over 20% in several healthcare systems. Approximately 59% of syphilis testing is performed using treponemal assays, while 41% utilizes non-treponemal methods. Prenatal screening programs account for nearly 36% of total syphilis testing volumes. Hospitals and public health facilities perform approximately 72% of diagnostic confirmations. Rapid syphilis tests now represent nearly 24% of screening procedures, reducing turnaround times from 48 hours to less than 30 minutes in many healthcare environments.

HIV: HIV testing accounts for approximately 24% of the Diagnostic Testing of STDs Market Share and remains one of the most established diagnostic segments. More than 39 million individuals are living with HIV globally. Around 86% of diagnosed patients are aware of their status due to expanded testing programs. Rapid HIV testing contributes approximately 34% of testing procedures, while laboratory-based molecular testing accounts for nearly 52%. More than 110 countries have implemented national HIV screening strategies. Community-based testing initiatives contribute around 21% of annual HIV tests. Fourth-generation HIV assays achieve sensitivity rates above 99%, supporting early detection and reinforcing demand within the Diagnostic Testing of STDs Industry Analysis.

HPV + Pap Smear: HPV and Pap smear testing contributes approximately 14% of total Diagnostic Testing of STDs Market Size. More than 690 million individuals globally carry HPV infections, making it one of the most prevalent sexually transmitted infections. Approximately 65% of cervical cancer screening programs incorporate HPV testing alongside Pap smear evaluation. Women aged 25–65 years account for nearly 82% of testing volumes. Molecular HPV testing demonstrates detection accuracy exceeding 94% in many clinical studies. More than 70 countries have expanded HPV screening recommendations. Automated cytology systems currently process approximately 45% of Pap smear examinations, improving workflow efficiency and supporting Diagnostic Testing of STDs Market Opportunities.

HSV: HSV testing accounts for approximately 6% of the Diagnostic Testing of STDs Market Share. More than 3.8 billion people under the age of 50 years carry HSV-1 infection globally, while approximately 520 million individuals live with HSV-2. Serological assays represent nearly 57% of HSV diagnostic procedures, while molecular tests contribute approximately 31%. Women account for nearly 54% of testing demand. Hospital laboratories conduct around 62% of HSV diagnostic confirmations. Point-of-care testing adoption has increased by approximately 19% over the past several years. Growing awareness campaigns and reproductive health screening initiatives continue to support expansion within the Diagnostic Testing of STDs Market Report.

Chancroid: Chancroid testing represents approximately 2% of the Diagnostic Testing of STDs Market Share. Although incidence rates have declined significantly, outbreaks continue to occur in specific regions. Approximately 48% of chancroid testing is performed in specialized infectious disease clinics. Molecular diagnostic methods account for nearly 52% of laboratory confirmations, while culture-based methods contribute around 28%. Public health surveillance programs perform approximately 40% of testing procedures in affected regions. Healthcare providers increasingly utilize multiplex testing platforms capable of identifying chancroid alongside other sexually transmitted infections.

By Application

Hospitals: Hospitals account for approximately 57% of the Diagnostic Testing of STDs Market Share. Large healthcare facilities process more than 65% of high-complexity diagnostic tests, including molecular assays and multiplex screening procedures. Approximately 72% of HIV confirmations, 69% of syphilis confirmations, and 64% of gonorrhea diagnoses occur in hospital laboratories. Automated analyzers capable of processing over 1,000 samples per day are installed in many tertiary care institutions. Around 76% of hospital laboratories utilize integrated digital reporting systems. Hospitals remain the primary users of advanced molecular diagnostics, supporting Diagnostic Testing of STDs Market Trends through investment in automation, workflow optimization, and rapid testing technologies.

Clinics: Clinics represent approximately 43% of the Diagnostic Testing of STDs Market Size. Community health centers, sexual health clinics, and outpatient facilities perform nearly 48% of routine screening procedures. Point-of-care diagnostics account for approximately 37% of clinic-based testing activity because results can be delivered within 15–30 minutes. Nearly 55% of first-time screening patients access services through clinics rather than hospitals. Self-collection and self-testing initiatives are utilized by approximately 26% of clinic patients. Clinics play a vital role in expanding healthcare accessibility, particularly among younger populations aged 18–34 years, supporting Diagnostic Testing of STDs Market Growth through preventive screening programs.

Regional Outlook

The Diagnostic Testing of STDs Market demonstrates strong regional variation driven by healthcare infrastructure, screening programs, and diagnostic accessibility. North America leads with approximately 38% market share, followed by Europe at 27%, Asia-Pacific at 24%, and Middle East & Africa at 11%. Increasing adoption of molecular diagnostics, expanding public health screening initiatives, and growing utilization of rapid testing technologies continue to support testing volumes across all major regions.

Download FREE Sample to learn more about this report.

North America

North America accounts for approximately 38% of the Diagnostic Testing of STDs Market Share and remains the largest regional contributor due to advanced healthcare infrastructure, extensive laboratory networks, and strong public health surveillance programs. More than 80 million STD diagnostic procedures are conducted annually across the region, reflecting widespread screening adoption and high awareness levels. The United States contributes nearly 84% of regional testing activity, while Canada accounts for approximately 11%, supported by organized screening initiatives and preventive healthcare programs. Molecular diagnostic technologies represent around 67% of testing procedures, enabling faster and more accurate detection of infections.

Chlamydia testing leads regional demand with nearly 31% of total screening volumes, while HIV testing contributes approximately 26%. Hospitals account for about 59% of testing demand because of their advanced laboratory capabilities, whereas clinics contribute 41% through community-based screening services. More than 75% of healthcare providers recommend routine STD screening for high-risk populations, supporting early diagnosis and treatment. Rapid testing technologies have achieved adoption levels exceeding 34%, improving turnaround times and patient management outcomes. Digital reporting systems are now implemented in over 70% of laboratories, enhancing disease surveillance, reporting accuracy, and healthcare coordination. These factors collectively strengthen North America’s leadership position in the Diagnostic Testing of STDs Market.

Europe

Europe represents approximately 27% of the Diagnostic Testing of STDs Market Size and benefits from strong healthcare systems, government-supported screening initiatives, and standardized diagnostic protocols. More than 45 million diagnostic tests are performed annually across the region, demonstrating significant demand for preventive and routine sexual health services. Germany, France, the United Kingdom, Italy, and Spain collectively account for nearly 68% of European testing volumes, making them the primary contributors to regional growth. Approximately 61% of laboratories utilize molecular diagnostic platforms, supporting high diagnostic accuracy and efficient disease detection. Chlamydia testing represents nearly 30% of total screening procedures, while HIV testing contributes around 22%, reflecting the prevalence of these infections across multiple countries.

Public healthcare clinics account for approximately 46% of regional testing activity, whereas hospitals contribute 54% due to their broader diagnostic capabilities. Self-collection testing methods have expanded to approximately 17% of screening procedures, increasing accessibility and patient convenience. Prenatal screening programs include syphilis testing in nearly 90% of pregnancies in several countries, strengthening maternal and neonatal health outcomes. National healthcare systems support routine screening initiatives covering more than 120 million individuals, reinforcing preventive healthcare efforts. Continued investment in laboratory modernization and digital health integration supports sustained Diagnostic Testing of STDs Market development throughout Europe.

Asia-Pacific

Asia-Pacific holds approximately 24% of the Diagnostic Testing of STDs Market Share and represents one of the most dynamic regions due to its large population base, expanding healthcare infrastructure, and increasing awareness of sexually transmitted infections. The region contains more than 60% of the global population, creating substantial demand for diagnostic services and screening programs. China, India, Japan, South Korea, and Australia collectively contribute approximately 71% of regional testing procedures. Chlamydia and gonorrhea testing together account for nearly 44% of total testing demand, reflecting the need for widespread screening and disease management. Government-supported screening initiatives reach more than 200 million individuals annually, significantly expanding diagnostic access.

Molecular diagnostic adoption has increased to approximately 49%, compared with 35% a decade earlier, demonstrating rapid technological advancement. Hospitals account for nearly 63% of testing activity due to higher patient volumes and laboratory resources, while clinics contribute approximately 37% through outpatient services and community healthcare programs. Rapid diagnostic tests represent around 29% of procedures, supporting quicker diagnosis in both urban and rural settings. Growing laboratory capacity, digital health platforms, and public awareness campaigns continue to improve testing accessibility and efficiency. These developments create substantial opportunities for innovation, investment, and service expansion across the Asia-Pacific Diagnostic Testing of STDs Market.

Middle East & Africa

Middle East & Africa accounts for approximately 11% of the Diagnostic Testing of STDs Market Size and continues to expand through improvements in healthcare access, laboratory infrastructure, and public health awareness initiatives. More than 20 million diagnostic tests are conducted annually across the region, indicating steady progress in screening and disease detection capabilities. South Africa, Saudi Arabia, the United Arab Emirates, Egypt, and Nigeria collectively contribute approximately 58% of regional testing volumes. HIV testing represents nearly 33% of total diagnostic activity, reflecting ongoing public health priorities and targeted screening efforts. Public healthcare institutions perform approximately 68% of screening procedures, while private facilities contribute 32%, creating a balanced diagnostic ecosystem.

Point-of-care testing accounts for nearly 36% of regional diagnostic activity, improving access to testing services in underserved and remote communities. Approximately 54% of healthcare facilities utilize electronic reporting systems, strengthening disease monitoring and healthcare data management. Government-supported awareness campaigns have increased screening participation by approximately 22% in several countries, encouraging earlier diagnosis and treatment. Investments in laboratory modernization, healthcare workforce training, and donor-supported health programs continue to improve diagnostic capabilities. These advancements support broader screening coverage, enhanced disease surveillance, and sustained growth within the Diagnostic Testing of STDs Market across the region.

List of Top Diagnostic Testing of STDs Companies

• Roche Holdings AG – Approximately 18% market share, presence in more than 100 countries, with over 60% of STD testing portfolio based on molecular diagnostics.
• Hologic, Inc. – Approximately 14% market share, with more than 50% of installations focused on high-throughput molecular screening platforms and automated diagnostic workflows.

Investment Analysis and Opportunities

The Diagnostic Testing of STDs Market Opportunities continue to expand as healthcare providers increase investments in molecular diagnostics, rapid testing technologies, and digital healthcare infrastructure. Approximately 58% of recent diagnostic investments have targeted molecular testing platforms due to sensitivity rates exceeding 95%. Automated laboratory systems now account for nearly 47% of capital equipment purchases across diagnostic facilities. Point-of-care diagnostics represent a major investment segment, contributing approximately 27% of testing procedures globally. Healthcare organizations report that rapid testing systems reduce patient follow-up losses by nearly 40%. More than 60 countries have expanded public screening initiatives, creating opportunities for equipment suppliers, reagent manufacturers, and software providers.

Digital health integration also represents a growing opportunity. Approximately 49% of laboratories now utilize electronic reporting systems, while 35% have implemented cloud-based diagnostic management platforms. Self-testing and home-collection kits account for nearly 22% of new product investments, reflecting changing patient preferences. Emerging markets contribute significant expansion potential, with healthcare infrastructure investments increasing laboratory capacity by approximately 18% in several developing regions. Multiplex testing platforms capable of detecting 3–7 infections simultaneously are attracting substantial procurement activity. These factors continue to support Diagnostic Testing of STDs Market Forecast and long-term industry expansion.

New Product Development

Innovation remains a central factor in the Diagnostic Testing of STDs Market, with manufacturers focusing on rapid diagnostics, multiplex assays, automation, connectivity, and decentralized testing solutions. Approximately 63% of newly launched STD diagnostic products feature multiplex testing capabilities capable of detecting 3 to 8 sexually transmitted infections from a single specimen. These platforms reduce laboratory processing requirements by nearly 40% and decrease turnaround times by approximately 55% compared with conventional testing workflows. Rapid molecular testing systems have gained substantial attention, with nearly 46% of recent product launches delivering results in less than 30 minutes. Several next-generation platforms demonstrate sensitivity levels above 95% and specificity rates exceeding 98% for infections including chlamydia, gonorrhea, HIV, and syphilis. Compact analyzers weighing less than 15 kilograms now support decentralized testing environments, allowing deployment across clinics, pharmacies, and community health centers.

Home-based testing innovation has accelerated significantly. Approximately 22% of new diagnostic products are designed for self-collection or self-testing applications. Studies indicate that self-collection kits improve screening participation by nearly 35% among previously underserved populations. Digital integration is another major focus area, with approximately 49% of recently introduced systems incorporating mobile applications, cloud-based reporting, or electronic health record connectivity. Artificial intelligence-assisted diagnostic interpretation has been integrated into approximately 18% of advanced testing platforms. These systems improve workflow efficiency by nearly 30% and reduce manual review requirements by approximately 25%. Manufacturers are also introducing automated sample preparation modules that decrease technician handling time by more than 50%. Another significant trend involves high-throughput molecular analyzers capable of processing over 1,500 samples per day. These systems are increasingly utilized in national screening programs and large hospital laboratories.

Five Recent Developments (2023–2025)

• Roche Holdings AG, In 2024, Roche upgraded molecular STD diagnostics, increasing laboratory throughput by 35% and enabling processing of over 1,000 samples daily.
• Hologic, Inc., In 2024, Hologic enhanced multiplex testing systems detecting 4 infections simultaneously, reducing diagnostic turnaround times by approximately 50%.
• Becton Dickinson & Company, In 2023, Becton Dickinson expanded rapid STD testing deployment, increasing testing accessibility by approximately 28% across participating facilities.
• BioMérieux, In 2025, bioMérieux introduced automation upgrades, improving sample processing speed by approximately 30% and strengthening digital reporting integration.
• binx health, In 2024, binx health expanded near-patient molecular testing, delivering results within 30 minutes and improving treatment initiation rates.

Report Coverage of Diagnostic Testing of STDs Market

The Diagnostic Testing of STDs Market Report provides extensive evaluation of market structure, testing technologies, disease categories, healthcare applications, regional performance, competitive positioning, innovation trends, and investment opportunities. The report examines more than 7 major disease segments, including chlamydia, gonorrhea, syphilis, HIV, HPV with Pap smear, HSV, and chancroid. The Diagnostic Testing of STDs Market Analysis includes assessment of molecular diagnostics, rapid testing technologies, immunoassays, laboratory automation systems, and digital healthcare integration platforms. Approximately 58% of testing procedures are currently performed using molecular diagnostic technologies, while rapid diagnostics contribute nearly 24% of total testing activity. These figures are evaluated alongside laboratory workflow developments and adoption trends.

The report analyzes application performance across hospitals and clinics. Hospitals account for approximately 57% of global testing activity, while clinics contribute nearly 43%. The analysis also examines patient screening behavior, testing accessibility, public health initiatives, and disease surveillance programs impacting market demand. Regional assessment covers North America, Europe, Asia-Pacific, and Middle East & Africa. Together, North America and Europe account for approximately 65% of global testing activity, while Asia-Pacific contributes nearly 24% and Middle East & Africa approximately 11%. The report evaluates healthcare infrastructure, diagnostic capacity, regulatory environments, and adoption patterns across each region.